{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:07:03Z","timestamp":1782252423264,"version":"3.54.5"},"reference-count":29,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,5,1]]},"abstract":"<jats:p>Resistin is an adipokine with putative prodiabetogenic properties. Like other hormones secreted by adipose tissue, resistin is being investigated as a possible etiologic link between excessive adiposity and insulin resistance. Although there is growing evidence that circulating levels of this adipokine are proportional to the degree of adiposity, an effect on insulin resistance in humans remains unproven. To evaluate the relations among resistin, obesity, and insulin resistance, we measured fasting serum resistin levels in 113 nondiabetic (75-g oral glucose tolerance test) Pima Indians (ages 29 \u00b1 7 years, body fat 31 \u00b1 8%, resistin 3.7 \u00b1 1.1 ng\/ml [means \u00b1 SD]), who were characterized for body composition (assessed by hydrodensitometry or dual-energy X-ray absorptiometry), whole-body insulin sensitivity (M; assessed by hyperinsulinemic clamp), basal hepatic glucose output (BHGO) and hepatic glucose output during low-dosage insulin infusion of a hyperinsulinemic clamp (HGO; a measure of hepatic insulin resistance), and acute insulin secretory response (AIR; assessed by 25-g intravenous glucose tolerance test). Follow-up measurements of M, BHGO, HGO, and AIR were available for 34 subjects who had normal glucose tolerance at baseline and remained nondiabetic at follow-up. The average time to follow-up was 4.5 \u00b1 2.7 years. In cross-sectional analyses, serum resistin levels were positively associated with percent body fat (r = 0.37, P = 0.0001) and 2-h glucose (r = 0.19, P = 0.04), respectively. Serum resistin levels were not associated with fasting glucose and insulin levels, M, BHGO, HGO, or AIR (r = 0.17, 0.12, \u22120.13, \u22120.06, \u22120.03, and \u22120.04, respectively; all P &amp;gt; 0.05). After adjusting for percent body fat, there was no association between serum resistin levels and 2-h glucose (r = 0.06, P = 0.6). In prospective analyses, high serum resistin levels at baseline were not associated with a decline in M (r = \u22120.1, P &amp;gt; 0.5). Resistin levels were, however, associated with increases in percent body fat, fasting plasma insulin, and HGO (r = 0.34, 0.36, and 0.37; all P &amp;lt; 0.05) after adjusting for sex, age, and time to follow-up. After additional adjustment for the change in percent body fat, there was no association between baseline serum resistin levels and changes in plasma insulin or HGO (r = 0.26 and 0.23; both P &amp;gt; 0.1). We conclude that in Pima Indians, like other human populations, circulating resistin levels are proportional to the degree of adiposity, but not the degree of insulin resistance. We unexpectedly found that high serum resistin levels do predict future increases in percent body fat. Our data suggest that resistin promotes obesity but not obesity-associated insulin resistance in humans.<\/jats:p>","DOI":"10.2337\/diabetes.53.5.1279","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T19:04:22Z","timestamp":1173207862000},"page":"1279-1284","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":113,"title":["High Serum Resistin Is Associated With an Increase in Adiposity But Not a Worsening of Insulin Resistance in Pima Indians"],"prefix":"10.2337","volume":"53","author":[{"given":"Barbora","family":"Vozarova de Courten","sequence":"first","affiliation":[{"name":"Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Degawa-Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Metabolism, Indiana University, School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"Considine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Metabolism, Indiana University, School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Antonio","family":"Tataranni","sequence":"additional","affiliation":[{"name":"Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031218100662800_R1","doi-asserted-by":"crossref","unstructured":"Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest\u2008106:473\u2013481,2000","DOI":"10.1172\/JCI10842"},{"key":"2022031218100662800_R2","doi-asserted-by":"crossref","unstructured":"Porte D Jr, Baskin DG, Schwartz MW: Leptin and insulin action in the central nervous system. Nutr Rev\u200860:S20\u2013S29,2002","DOI":"10.1301\/002966402320634797"},{"key":"2022031218100662800_R3","doi-asserted-by":"crossref","unstructured":"Tsao TS, Lodish HF, Fruebis J: ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol\u2008440:213\u2013221,2002","DOI":"10.1016\/S0014-2999(02)01430-9"},{"key":"2022031218100662800_R4","doi-asserted-by":"crossref","unstructured":"Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA: A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A\u200898:502\u2013506,2001","DOI":"10.1073\/pnas.98.2.502"},{"key":"2022031218100662800_R5","doi-asserted-by":"crossref","unstructured":"Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature\u2008409:307\u2013312,2001","DOI":"10.1038\/35053000"},{"key":"2022031218100662800_R6","doi-asserted-by":"crossref","unstructured":"Rajala MW, Obici S, Scherer PE, Rossetti L: Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest\u2008111:225\u2013230,2003","DOI":"10.1172\/JCI16521"},{"key":"2022031218100662800_R7","doi-asserted-by":"crossref","unstructured":"Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N: Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol\u2008285:E106\u2013E115,2003","DOI":"10.1152\/ajpendo.00457.2002"},{"key":"2022031218100662800_R8","doi-asserted-by":"crossref","unstructured":"Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O\u2019Rahilly S: Resistin\/fizz3 expression in relation to obesity and peroxisome proliferator\u2013activated receptor-\u03b3 action in humans. Diabetes\u200850:2199\u20132202,2001","DOI":"10.2337\/diabetes.50.10.2199"},{"key":"2022031218100662800_R9","doi-asserted-by":"crossref","unstructured":"Nagaev I, Smith U: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun\u2008285:561\u2013564,2001","DOI":"10.1006\/bbrc.2001.5173"},{"key":"2022031218100662800_R10","doi-asserted-by":"crossref","unstructured":"McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S: Resistin, central obesity, and type 2 diabetes (Letter). Lancet\u2008359:46\u201347,2002","DOI":"10.1016\/S0140-6736(02)07281-1"},{"key":"2022031218100662800_R11","doi-asserted-by":"crossref","unstructured":"McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S: Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab\u200887:2407,2002","DOI":"10.1210\/jcem.87.5.8627"},{"key":"2022031218100662800_R12","doi-asserted-by":"crossref","unstructured":"Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res\u200810:1\u20135,2002","DOI":"10.1038\/oby.2002.1"},{"key":"2022031218100662800_R13","doi-asserted-by":"crossref","unstructured":"Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun\u2008300:472\u2013476,2003","DOI":"10.1016\/S0006-291X(02)02841-3"},{"key":"2022031218100662800_R14","doi-asserted-by":"crossref","unstructured":"Degawa-Yamauchi MBJE, Juliar BE, Watson W, Kerr K, Jones RM, Zhu Q, Considine RV: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab\u200888:5452\u20135455,2003","DOI":"10.1210\/jc.2002-021808"},{"key":"2022031218100662800_R15","doi-asserted-by":"crossref","unstructured":"Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab\u200888:1730\u20131736,2003","DOI":"10.1210\/jc.2002-021604"},{"key":"2022031218100662800_R16","doi-asserted-by":"crossref","unstructured":"Knowler WC, Pettitt DJ, Saad MF, Bennett PH: Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev\u20086:1\u201327,1990","DOI":"10.1002\/dmr.5610060101"},{"key":"2022031218100662800_R17","doi-asserted-by":"crossref","unstructured":"Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med\u2008329:1988\u20131992,1993","DOI":"10.1056\/NEJM199312303292703"},{"key":"2022031218100662800_R18","unstructured":"World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Organization,1985 (Tech. Rep. Ser., no. 727)"},{"key":"2022031218100662800_R19","unstructured":"Siri WE: Body composition from fluid spaces and density: analysis of methods. In Techniques for Measuring Body Composition. Brozek J, Hanschel A, Eds. Washington, DC, National Academy of Sciences,1961, p.223\u2013244"},{"key":"2022031218100662800_R20","doi-asserted-by":"crossref","unstructured":"Tataranni PA, Ravussin E: Use of dual-energy X-ray absorptiometry in obese individuals. Am J Clin Nutr\u200862:730\u2013734,1995","DOI":"10.1093\/ajcn\/62.4.730"},{"key":"2022031218100662800_R21","doi-asserted-by":"crossref","unstructured":"Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C: Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med\u2008318:1217\u20131225,1988","DOI":"10.1056\/NEJM198805123181901"},{"key":"2022031218100662800_R22","doi-asserted-by":"crossref","unstructured":"Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology\u20081:43\u201346,1990","DOI":"10.1097\/00001648-199001000-00010"},{"key":"2022031218100662800_R23","doi-asserted-by":"crossref","unstructured":"Hegele RA, Kraw ME, Ban MR, Miskie BA, Huff MW, Cao H: Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A\/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vasc Biol\u200823:111\u2013116,2003","DOI":"10.1161\/01.ATV.0000047460.27435.B8"},{"key":"2022031218100662800_R24","doi-asserted-by":"crossref","unstructured":"Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D: Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis\u200842:62\u201366,2003","DOI":"10.1016\/S0272-6386(03)00409-8"},{"key":"2022031218100662800_R25","doi-asserted-by":"crossref","unstructured":"Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes\u200851:1884\u20131888,2002","DOI":"10.2337\/diabetes.51.6.1884"},{"key":"2022031218100662800_R26","doi-asserted-by":"crossref","unstructured":"Lindsay RS, Funahashi T, Hanson R, Matsuzawa Y, Tanaka S, Tataranni PA., Knowler WC, Krakoff J: Adiponectin protects against development of type 2 diabetes in Pima Indian population. Lancet\u2008360:57\u201358,2002","DOI":"10.1016\/S0140-6736(02)09335-2"},{"key":"2022031218100662800_R27","doi-asserted-by":"crossref","unstructured":"Kim KH, Lee K, Moon YS, Sul HS: A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem\u2008276:11252\u201311256,2001","DOI":"10.1074\/jbc.C100028200"},{"key":"2022031218100662800_R28","doi-asserted-by":"crossref","unstructured":"Villena JA, Kim KH, Sul HS: Pref-1 and ADSF\/resistin: two secreted factors inhibiting adipose tissue development. Horm Metab Res\u200834:664\u2013670,2002","DOI":"10.1055\/s-2002-38244"},{"key":"2022031218100662800_R29","doi-asserted-by":"crossref","unstructured":"McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PMS, Smith SA, Barnett AH, Kumar S: Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab\u200888:6098\u20136106,2003","DOI":"10.1210\/jc.2003-030898"}],"updated-by":[{"DOI":"10.2337\/diabetes.53.9.2518","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000}}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/53\/5\/1279\/647063\/zdb00504001279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/53\/5\/1279\/647063\/zdb00504001279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:22:06Z","timestamp":1667406126000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/53\/5\/1279\/25833\/High-Serum-Resistin-Is-Associated-With-an-Increase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.53.5.1279","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}